Currently, the company is applying its Lecinoxoid technology to anti-inflammatory indications, including psoriasis and ulcerative colitis.
The latest patent provides intellectual property rights in validated European countries through 2029.
The company said that lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids.
VBL Therapeutics chief executive officer Dror Harats said: "This granted patent is an important addition to VBL’s Lecinoxoids intellectual property portfolio, which now includes more than 70 issued patents and pending patent applications worldwide.
"VBL is committed to continuing to expand and strengthen our pipeline through multiple layers of intellectual property protection. We look forward to leveraging our second-generation molecules to additional immune-inflammatory indications in broad patient populations."
Recently, the company had completed two Phase II trials evaluating the efficacy of lead Lecinoxoid compound, VB-201, to treat psoriasis and ulcerative colitis.
Top line results from the two trials are expected to be reported in the first quarter of 2015.
VBL’s Lecinoxoid platform technology includes a family of orally administered small molecules designed to modulate the body’s inflammatory response.